Novartis Ag (NVS) 80.36 $NVS Alcon launches the
Post# of 273246
Posted On: 09/08/2016 3:19:13 AM
Novartis Ag (NVS) 80.36 $NVS
Alcon launches the NGENUITY(R) 3D Visualization System designed to further enhance retinal surgeon experience
Globe Newswire - 2 hrs 3 mins ago
Novartis International AG / Alcon launches the NGENUITY(R) 3D Visualization System designed to further enhance retinal surgeon experience . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 80.36 (+0.21)
Post Earnings Coverage as Cooper Cos Earnings Grows 97 Percent
ACCESSWIRE - Wed Sep 07, 8:16AM CDT
LONDON, UK / ACCESSWIRE / September 7, 2016 / Active Wall St. announces its post-earnings coverage on The Cooper Companies Inc. (NYSE: COO). The company released its financial results for the fiscal third quarter 2016 (Q3 FY16) on September 1, 2016. The Contact-lens company updated its financial guidance after stellar earnings results. Register with us now for your free membership at: http://www.activewallst.com/register/.
JNJ: 119.61 (-0.14), VRX: 30.27 (+0.80), COO: 188.56 (+0.26), NVS: 80.36 (+0.21), VRX.TO: 39.05 (+1.19)
Influenza Market 2015-2020: Global Industry Perspective, Comprehensive Analysis and Forecasts Featuring AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis, Sanofi-Pasteur - Research and Markets
BusinessWire - Wed Sep 07, 3:35AM CDT
Research and Markets has announced the addition of the "Influenza Market (H1N1 Vaccines and Others) by Product (Influenza Vaccines and Influenza Drugs): Global Industry Perspective, Comprehensive Analysis and Forecast 2014 - 2020" report to their offering.
NVS: 80.36 (+0.21)
Foundation Fighting Blindness Sponsors Presentation by Retina Specialist James M. Maisel, M.D. on Macular Degeneration and Hereditary Retinal Degeneration
PRWeb - Wed Sep 07, 3:03AM CDT
James Maisel, MD will present "Macular Degeneration and Hereditary Retinal Degeneration" for the Foundation Fighting Blindness, Long Island Chapter Speaking Series, on September, 2016, 1:30-3:00 pm at the Farmingdale Public Library. The presentation is free to the public.
AGN: 238.42 (-0.70), NVS: 80.36 (+0.21)
Novartis (NVS) Reports Positive Data on Ultibro Breezhaler
Zacks Equity Research - Zacks Investment Research - Tue Sep 06, 8:38AM CDT
Novartis Pharma AG (NVS) announced positive results from a head-to-head study, FLAME, on COPD drug Ultibro Breezhaler.
ANIP: 60.71 (-0.84), CORT: 5.71 (+0.23), PCRX: 40.54 (-0.25), NVS: 80.36 (+0.21)
Pharmaceutical Products and CMO Market is Expanding at a CAGR 11.6% by 2024; Improving Regulatory Scenario Across Latin America Market: Transparency Market Research
PR Newswire Europe - Tue Sep 06, 8:31AM CDT
ALBANY, New York, September 6, 2016 /PRNewswire/ --
PFE: 34.84 (+0.07), NVS: 80.36 (+0.21)
Brazilian Pharmaceutical Market Outlook 2016-2026
PR Newswire Europe - Tue Sep 06, 8:03AM CDT
LONDON, September 6, 2016 /PRNewswire/ --
NVS: 80.36 (+0.21)
ROX Medical Raises $40M Financing
PR Newswire Europe - Tue Sep 06, 12:01AM CDT
ROX Medical, a privately held clinical-stage medical device company developing technologies for hypertension, announced today that it has secured $40M in Series E financing. Novartis Venture Fund and Apple Tree Partners led the round, joined by previous investors Versant Ventures and Domain Associates.
NVS: 80.36 (+0.21)
Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H2, 2016 - Analysis, Technologies & Forecasts - Key Vendors: Biogen, Sanofi, Novartis - Research and Markets
BusinessWire - Mon Sep 05, 10:12AM CDT
Research and Markets has announced the addition of the "Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H2, 2016" clinical trials to their offering.
NVS: 80.36 (+0.21)
Novartis' Ultibro(R) Breezhaler(R) consistently more effective than Seretide(R)* in reducing COPD flare-ups across different patient groups
Globe Newswire - Sat Sep 03, 12:15AM CDT
Novartis International AG / Novartis' Ultibro(R) Breezhaler(R) consistently more effective than Seretide(R)* in reducing COPD flare-ups across different patient groups . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 80.36 (+0.21)
Array (ARRY) Oncology Drug Accepted for Review in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:29AM CDT
Array BioPharma (ARRY) announced that the FDA has accepted a New Drug Application (NDA) for its oncology candidate, binimetinib.
CORT: 5.71 (+0.23), PCRX: 40.54 (-0.25), ARRY: 3.60 (unch), NVS: 80.36 (+0.21)
Pharma Stock Roundup: Mylan EpiPen Pricing in Focus, FDA Nod For Novartis Biosimilar
Arpita Dutt - Zacks Investment Research - Fri Sep 02, 8:17AM CDT
Drug pricing is back in focus with lawmakers questioning Mylan's (MYL) pricing policy for EpiPen.
MRK: 62.87 (-0.37), MYL: 40.31 (-0.09), TEVA: 51.29 (-0.04), BMY: 56.57 (-0.39), NVS: 80.36 (+0.21)
Blog Coverage FDA Approves Novartis Erelzi as Biosimilar to Amgen's Enbrel
ACCESSWIRE - Thu Sep 01, 8:15AM CDT
LONDON, UK / ACCESSWIRE / September 1, 2016 / Active Wall St. blog coverage looks at the headline from Novartis AG (NYSE: NVS). On August 30, 2016, the US Food and Drug Administration (FDA) approved Novartis AG's drug Erelzi which is a biosimilar to Amgen Inc.'s (NASDAQ: AMGN) Enbrel. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
JNJ: 119.61 (-0.14), PFE: 34.84 (+0.07), AMGN: 170.63 (-0.21), NVS: 80.36 (+0.21)
Novartis (NVS) Gets FDA Nod for Biosimilar Version of Enbrel
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:59AM CDT
Novartis (NVS) received a major boost when its generic arm, Sandoz obtained FDA approval for Erelzi, the biosimilar version of Amgen???s blockbuster drug Enbrel (etanercept).
PFE: 34.84 (+0.07), AMGN: 170.63 (-0.21), NVS: 80.36 (+0.21)
AirFluSal(R) Forspiro(R) showed superiority at 12 months over Seretide(R) Diskus(R)[1] in persistence to treatment
Globe Newswire - Wed Aug 31, 12:15AM CDT
Novartis International AG / AirFluSal(R) Forspiro(R) showed superiority at 12 months over Seretide(R) Diskus(R)[1] in persistence to treatment . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 80.36 (+0.21)
FDA approves Sandoz Erelzi(TM) to treat multiple inflammatory diseases
Globe Newswire - Tue Aug 30, 3:01PM CDT
Novartis International AG / FDA approves Sandoz Erelzi(TM) to treat multiple inflammatory diseases . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 80.36 (+0.21)
Your Complete Guide to the Generic Drug Industry
Ryan McQueeney - Zacks Investment Research - Mon Aug 29, 4:13PM CDT
Today we'll take a look at how generics are developed and how they affect the drug industry today.
AGN: 238.42 (-0.70), GNRX: 24.86 (+0.46), PRGO: 90.39 (-1.68), AXGN: 9.00 (+0.06), AKRX: 26.69 (+0.23), MYL: 40.31 (-0.09), TEVA: 51.29 (-0.04), AMPH: 19.03 (+0.12), NVS: 80.36 (+0.21)
Alcon launches the NGENUITY(R) 3D Visualization System designed to further enhance retinal surgeon experience
Globe Newswire - 2 hrs 3 mins ago
Novartis International AG / Alcon launches the NGENUITY(R) 3D Visualization System designed to further enhance retinal surgeon experience . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 80.36 (+0.21)
Post Earnings Coverage as Cooper Cos Earnings Grows 97 Percent
ACCESSWIRE - Wed Sep 07, 8:16AM CDT
LONDON, UK / ACCESSWIRE / September 7, 2016 / Active Wall St. announces its post-earnings coverage on The Cooper Companies Inc. (NYSE: COO). The company released its financial results for the fiscal third quarter 2016 (Q3 FY16) on September 1, 2016. The Contact-lens company updated its financial guidance after stellar earnings results. Register with us now for your free membership at: http://www.activewallst.com/register/.
JNJ: 119.61 (-0.14), VRX: 30.27 (+0.80), COO: 188.56 (+0.26), NVS: 80.36 (+0.21), VRX.TO: 39.05 (+1.19)
Influenza Market 2015-2020: Global Industry Perspective, Comprehensive Analysis and Forecasts Featuring AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis, Sanofi-Pasteur - Research and Markets
BusinessWire - Wed Sep 07, 3:35AM CDT
Research and Markets has announced the addition of the "Influenza Market (H1N1 Vaccines and Others) by Product (Influenza Vaccines and Influenza Drugs): Global Industry Perspective, Comprehensive Analysis and Forecast 2014 - 2020" report to their offering.
NVS: 80.36 (+0.21)
Foundation Fighting Blindness Sponsors Presentation by Retina Specialist James M. Maisel, M.D. on Macular Degeneration and Hereditary Retinal Degeneration
PRWeb - Wed Sep 07, 3:03AM CDT
James Maisel, MD will present "Macular Degeneration and Hereditary Retinal Degeneration" for the Foundation Fighting Blindness, Long Island Chapter Speaking Series, on September, 2016, 1:30-3:00 pm at the Farmingdale Public Library. The presentation is free to the public.
AGN: 238.42 (-0.70), NVS: 80.36 (+0.21)
Novartis (NVS) Reports Positive Data on Ultibro Breezhaler
Zacks Equity Research - Zacks Investment Research - Tue Sep 06, 8:38AM CDT
Novartis Pharma AG (NVS) announced positive results from a head-to-head study, FLAME, on COPD drug Ultibro Breezhaler.
ANIP: 60.71 (-0.84), CORT: 5.71 (+0.23), PCRX: 40.54 (-0.25), NVS: 80.36 (+0.21)
Pharmaceutical Products and CMO Market is Expanding at a CAGR 11.6% by 2024; Improving Regulatory Scenario Across Latin America Market: Transparency Market Research
PR Newswire Europe - Tue Sep 06, 8:31AM CDT
ALBANY, New York, September 6, 2016 /PRNewswire/ --
PFE: 34.84 (+0.07), NVS: 80.36 (+0.21)
Brazilian Pharmaceutical Market Outlook 2016-2026
PR Newswire Europe - Tue Sep 06, 8:03AM CDT
LONDON, September 6, 2016 /PRNewswire/ --
NVS: 80.36 (+0.21)
ROX Medical Raises $40M Financing
PR Newswire Europe - Tue Sep 06, 12:01AM CDT
ROX Medical, a privately held clinical-stage medical device company developing technologies for hypertension, announced today that it has secured $40M in Series E financing. Novartis Venture Fund and Apple Tree Partners led the round, joined by previous investors Versant Ventures and Domain Associates.
NVS: 80.36 (+0.21)
Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H2, 2016 - Analysis, Technologies & Forecasts - Key Vendors: Biogen, Sanofi, Novartis - Research and Markets
BusinessWire - Mon Sep 05, 10:12AM CDT
Research and Markets has announced the addition of the "Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H2, 2016" clinical trials to their offering.
NVS: 80.36 (+0.21)
Novartis' Ultibro(R) Breezhaler(R) consistently more effective than Seretide(R)* in reducing COPD flare-ups across different patient groups
Globe Newswire - Sat Sep 03, 12:15AM CDT
Novartis International AG / Novartis' Ultibro(R) Breezhaler(R) consistently more effective than Seretide(R)* in reducing COPD flare-ups across different patient groups . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 80.36 (+0.21)
Array (ARRY) Oncology Drug Accepted for Review in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:29AM CDT
Array BioPharma (ARRY) announced that the FDA has accepted a New Drug Application (NDA) for its oncology candidate, binimetinib.
CORT: 5.71 (+0.23), PCRX: 40.54 (-0.25), ARRY: 3.60 (unch), NVS: 80.36 (+0.21)
Pharma Stock Roundup: Mylan EpiPen Pricing in Focus, FDA Nod For Novartis Biosimilar
Arpita Dutt - Zacks Investment Research - Fri Sep 02, 8:17AM CDT
Drug pricing is back in focus with lawmakers questioning Mylan's (MYL) pricing policy for EpiPen.
MRK: 62.87 (-0.37), MYL: 40.31 (-0.09), TEVA: 51.29 (-0.04), BMY: 56.57 (-0.39), NVS: 80.36 (+0.21)
Blog Coverage FDA Approves Novartis Erelzi as Biosimilar to Amgen's Enbrel
ACCESSWIRE - Thu Sep 01, 8:15AM CDT
LONDON, UK / ACCESSWIRE / September 1, 2016 / Active Wall St. blog coverage looks at the headline from Novartis AG (NYSE: NVS). On August 30, 2016, the US Food and Drug Administration (FDA) approved Novartis AG's drug Erelzi which is a biosimilar to Amgen Inc.'s (NASDAQ: AMGN) Enbrel. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
JNJ: 119.61 (-0.14), PFE: 34.84 (+0.07), AMGN: 170.63 (-0.21), NVS: 80.36 (+0.21)
Novartis (NVS) Gets FDA Nod for Biosimilar Version of Enbrel
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:59AM CDT
Novartis (NVS) received a major boost when its generic arm, Sandoz obtained FDA approval for Erelzi, the biosimilar version of Amgen???s blockbuster drug Enbrel (etanercept).
PFE: 34.84 (+0.07), AMGN: 170.63 (-0.21), NVS: 80.36 (+0.21)
AirFluSal(R) Forspiro(R) showed superiority at 12 months over Seretide(R) Diskus(R)[1] in persistence to treatment
Globe Newswire - Wed Aug 31, 12:15AM CDT
Novartis International AG / AirFluSal(R) Forspiro(R) showed superiority at 12 months over Seretide(R) Diskus(R)[1] in persistence to treatment . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 80.36 (+0.21)
FDA approves Sandoz Erelzi(TM) to treat multiple inflammatory diseases
Globe Newswire - Tue Aug 30, 3:01PM CDT
Novartis International AG / FDA approves Sandoz Erelzi(TM) to treat multiple inflammatory diseases . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 80.36 (+0.21)
Your Complete Guide to the Generic Drug Industry
Ryan McQueeney - Zacks Investment Research - Mon Aug 29, 4:13PM CDT
Today we'll take a look at how generics are developed and how they affect the drug industry today.
AGN: 238.42 (-0.70), GNRX: 24.86 (+0.46), PRGO: 90.39 (-1.68), AXGN: 9.00 (+0.06), AKRX: 26.69 (+0.23), MYL: 40.31 (-0.09), TEVA: 51.29 (-0.04), AMPH: 19.03 (+0.12), NVS: 80.36 (+0.21)
(0)
(0)Scroll down for more posts ▼